Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lipid-lowering and antidiabetic activity of DRL-17564, a novel selective PPARgamma modulator

July 3, 2007

Diabetes snapshots: dipeptidyl peptidase IV inhibitors

July 3, 2007

Administration of a 11beta-HSD1 inhibitor in the evening improves metabolic parameters in DIO mice

July 3, 2007

Phase I study supports further clinical evaluation of eltrombopag

July 3, 2007

E1-I.N.T. yields sustained reductions in HbA1c levels in type 2 diabetes patients

July 3, 2007

Final ferumoxytol phase III results expected in summer

July 3, 2007

Wyeth licenses osteoporosis drug targets from Galapagos collaboration

July 2, 2007

New agents for endocrine-related disorders imparted in recent patent literature

July 2, 2007

Fertility treatment Pergoveris approved in E.U.

June 29, 2007

Randomization targets met in two phase III trials of corifollitropin alfa

June 29, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...